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Abstract
Background: While all anti-diabetic agents can decrease blood glucose level directly or indirectly,
few are able to protect and preserve both pancreatic beta cell mass and their insulin-secreting
functions. Thus, there is an urgent need to find an agent or combination of agents that can lower
blood glucose and preserve pancreatic beta cells at the same time. Herein, we report a dual-
functional andrographolide-lipoic acid conjugate (AL-1). The anti-diabetic and beta cell protective
activities of this novel andrographolide-lipoic acid conjugate were investigated.
Methods: In alloxan-treated mice (a model of type 1 diabetes), drugs were administered orally
once daily for 6 days post-alloxan treatment. Fasting blood glucose and serum insulin were
determined. Pathologic and immunohistochemical analysis of pancreatic islets were performed.
Translocation of glucose transporter subtype 4 in soleus muscle was detected by western blot. In
RIN-m cells in vitro, the effect of AL-1 on H2O2-induced damage and reactive oxidative species
production stimulated by high glucose and glibenclamide were measured. Inhibition of nuclear
factor kappa B (NF-κB) activation induced by IL-1β and IFN-γ was investigated.
Results: In alloxan-induced diabetic mouse model, AL-1 lowered blood glucose, increased insulin
and prevented loss of beta cells and their dysfunction, stimulated glucose transport protein subtype
4 (GLUT4) membrane translocation in soleus muscles. Pretreatment of RIN-m cells with AL-1
prevented H2O2-induced cellular damage, quenched glucose and glibenclamide-stimulated reactive
oxidative species production, and inhibited cytokine-stimulated NF-κB activation.
Conclusion: We have demonstrated that AL-1 had both hypoglycemic and beta cell protective
effects which translated into antioxidant and NF-κB inhibitory activity. AL-1 is a potential new anti-
diabetic agent.
Introduction
Diabetes mellitus has become an epidemic in the past sev-
eral decades owing to the advancing age of the popula-
tion, a substantially increased prevalence of obesity, and
reduced physical activity. The US Center for Disease Con-
trol and Prevention (CDC) estimates that 20.8 million
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betes in 2005 http://www.cdc.gov/diabetes/pubs/gen
eral.htm. Of this total, 1.5 million were newly diagnosed
and over 30% (6.2 million) were undiagnosed. In addi-
tion, 54 million people are estimated to have pre-diabe-
tes. Among those diagnosed with diabetes, 85% to 90%
have type 2 diabetes.
Type 1 diabetes is characterized by insulin deficiency, a
loss of the insulin-producing beta cells of the pancreatic
islets of Langerhans. Beta cell loss is largely caused by a T-
cell mediated autoimmune attack [1]. Type 2 diabetes is
preceded by insulin resistance or reduced insulin sensitiv-
ity, combined with reduced insulin secretion. Insulin
resistance forces pancreatic beta cells to produce more
insulin, which ultimately results in exhaustion of insulin
production secondary to deterioration of beta cell func-
tions. By the time diabetes is diagnosed, over 50% of beta
cell function is lost [2]. The gradual loss of beta cell func-
tion results in increased levels of blood glucose and ulti-
mate diabetes.
Recent availability of expanded treatment options for
both types 1 and 2 diabetes has not translated into easier
and significantly better glycemic and metabolic manage-
ment. Patients with type 1 diabetes continue to experience
increased risk of hypoglycemic episodes and progressive
weight gain resulting from intensive insulin treatment,
despite the availability of a variety of insulin analogs.
Given the progressive nature of the disease, most patients
with type 2 diabetes inevitably proceed from oral agent
monotherapy to combination therapy and, ultimately
require exogenous insulin replacement. Both type 1 and
type 2 diabetic patients continue to suffer from marked
postprandial hyperglycemia. None of the currently used
medications reverse ongoing failure of beta cell function
[3]. Thus, there is an urgent need to find an agent/combi-
nation of agents that can both lower blood glucose and
preserve the function of pancreatic beta cells.
Andrographis paniculata (A. paniculata) is a traditional Chi-
nese medicine used in many Asian countries for the treat-
ment of colds, fever, laryngitis and diarrhea. Studies of
plant extracts demonstrate immunological, antibacterial,
antiviral, anti-inflammatory, antithrombotic and hepato-
protective properties [4-8]. In Malaysia, this plant is used
in folk medicine to treat diabetes and hypertension [9].
An aqueous extract of A. paniculata was reported to
improve glucose tolerance in rabbits, and an ethanolic
extract demonstrated anti-diabetic properties in strepto-
zotocin (STZ)-induced diabetic rats [10].
Androdrographolide (Andro, Fig. 1), the primary active
component of A. paniculata, lowers plasma glucose in
STZ-diabetic rats by increasing glucose utilization [11].
The db/db diabetic mice progressively develop
insulinopenia with age, a feature commonly observed in
late stages of human type 2 diabetes when blood glucose
levels are not sufficiently controlled [12]. When an Andro
analog was administered orally to db/db mice at a dose of
100 mg/kg daily for 6 days, the blood glucose level
decreased by 64%, and plasma triglyceride level by 54%
[13]. These data showed that A. paniculata and Andro had
significant activity for diabetes.
Alpha-lipoic acid (LA, 1, 2-dithiolane-3-pentanoic acid,
Fig. 1), is one of the most potent antioxidants. Pharmaco-
logically, LA improves glycemic control and polyneuropa-
thies associated with diabetes mellitus, as well as
effectively mitigating toxicities associated with heavy
metal poisoning [14,15]. As an antioxidant, LA directly
terminates free radicals, chelates transition metal ions
(e.g., iron and copper), increases cytosolic glutathione
and vitamin C levels, and prevents toxicities associated
with their loss. These diverse actions suggest that LA acts
by multiple mechanisms both physiologically and phar-
macologically. For these reasons, LA is one of the most
widely used health supplements and has been licensed
and used for the treatment of symptomatic diabetic neu-
ropathy in Germany for more than 20 years.
Realizing the beneficial mechanisms of action and effects
of both Andro and LA for treatment of diabetes, we con-
ducted experiments to evaluate the efficacy and possible
mechanism(s) of action of a conjugate of Andro and LA,
i.e., andrographolide-lipoic acid conjugate (AL-1, Fig. 1),
in vitro and in experimental diabetic animal models.
Methods
Reagents
AL-1 was synthesized and purified in our laboratory [16].
Andro, LA, DMSO and glibenclamide were purchased
from Alfa Aesar (War Hill, MA, USA). Alloxan, leupeptin,
luminol were purchased from Sigma-Aldrich Corp. (St
Louis, MO, USA). pNF-κB-luc, PRL-TK plasmid and dual
luciferase reporter (DLR) assay kits were purchase from
Promega Corp. (Madison, WI, USA). Lipofectamine 2000
and Opti-MEM medium were purchased from Invitrogen
Corp. (Carlsbad, CA, USA). Mouse IL-1β and IFN-γ were
purchased from PeproTech (Rocky Hill, NJ, USA). Poly-
clone anti-GLUT4 antibody was purchased from Chemi-
con International Inc. (Temecula, CA, USA). Polyclone
anti-insulin antibody, ployclone anti-β-actin antibody
and HRP-conjugated goat anti-rabbit antibody were pur-
chased from Beijing Biosynthesis Biotechnology Co. Ltd.
(Beijing, China).
Diabetic mouse model
Female BALB/c mice, aged 6–8 weeks (18–22 g), were
obtained from the Experimental Animal Center of Guang-Page 2 of 13
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an animal room with 12 h light and 12 h dark, and were
maintained on standard pelleted diet with water ad libi-
tum. After fasting for 18 h, mice were injected via the tail
vein with a single dose of 60 mg/kg alloxan (Sigma-
Aldrich), freshly dissolved in 0.9% saline. Diabetes in
mice was identified by polydipsia, polyuria and by meas-
uring fasting serum glucose levels 72 h after injection of
alloxan. Mice with a blood glucose level above 16.7 mM
were used for experiments.
Diabetic mice were randomly divided into 6 groups of 6
mice. The first group was given vehicle (20% DMSO in
distilled water) as a diabetic control group; the 2nd, 3rd
and 4th groups were given AL-1 at doses of 20, 40 and 80
mg/kg, respectively; the 5th group was given Andro at 50
mg/kg (equal molar dose to 80 mg/kg AL-1); the 6th
group was given glibenclamide at 1.2 mg/kg as a positive
control. And 6 non-diabetic mice received vehicle as a
normal control group. On the 4th day after alloxan
administration, fasting (12–14 h) blood glucose levels
were measured using a complete blood glucose monitor-
ing system (Model: SureStep, LifeScan, Johson-Johson
Co., Shanghai, China). AL-1, Andro, glibenclamide and
vehicle were given by intragastric administration once
daily for 6 days, respectively. On the evening of day 6, all
mice were fasted overnight (12–14 h), and the following
morning, after blood glucose of all groups was measured,
animals were killed by decapitation. Blood was collected
by drainage from the retroorbital venous plexus and kept
on ice. Pancreas and soleus muscle were removed and
immediately frozen at -80°C for various assays. Clotted
blood samples were centrifuged at 3,000 × g for 15 min to
obtain serum. The levels of serum insulin were deter-
mined by chemiluminescent immunoassay using a com-
mercially available kit (Beijing Atom HighTech Co., Ltd.,
Beijing, China).
Pathologic and immunohistochemical analysis of pancreas
Pancreatic tissues were collected and placed in fixative (40
g/l formaldehyde solution in 0.1 M PBS) overnight, and
was washed with 0.1 M PBS, then paraffin embedded, sec-
tioned (2 μm), and stained with hematoxylin and eosin.
For immunostaining studies, rabbit anti-mouse insulin
antibody (1:50; Beijing Biosynthesis Biotechnology Co.
Ltd.) was incubated with the sample sections for 3 h at
37°C. Horseradish peroxidase (HRP)-conjugated goat
anti-rabbit IgG antibody (1:200; Beijing Biosynthesis Bio-
technology Co. Ltd.) was used for 3, 3'-diaminobenzidine
(DAB) coloration. Area of pancreatic islet was analyzed
using Olypus analySIS image analysis software (Olympus
Optical Co., Tokyo, Japan).
Western blot analysis of glucose transporter subtype 4 
(GLUT4) translocation
GLUT4 protein extract was prepared as described in
Takeuchi et al. [17] with modifications. Briefly, soleus
muscles were homogenized in an ice-cold buffer contain-
ing 20 mM HEPES, 250 mM sucrose, 2 mM EGTA, 0.2 mM
phenylmethylsulfonyl fluoride (PMSF), and 1 μM leupep-
tin (Sigma-Aldrich) at pH 7.4. Nuclei and unbroken cells
were removed by centrifugation at 2,000 × g for 10 min.
Total membrane fraction was prepared by centrifugation
of the supernatant in a super-speed centrifuge at 190,000
× g for 1 h at 4°C. The membrane pellets were re-sus-
pended in homogenization buffer and stored at -80°C.
Immunoblotting was performed using polyclonal anti-
GLUT4 antibody (1:2,000 dilution; Chemicon) at 4°C
overnight, and polyclonal anti-actin antibody (1:500
dilution; Beijing Biosynthesis Biotechnology Co. Ltd.)
was used as an inter-control. After washing with TBS-T, the
blots were incubated for 1 h at room temperature with
HRP-conjugated goat anti-rabbit antibodies (1:2,000
dilution; Beijing Biosynthesis Biotechnology Co. Ltd.),
and were detected using ECL Plus (PIERCE, Rockford, IL,
USA).
Cell culture
RIN-m cell is an insulinoma cell line derived from a rat
islet cell tumor [18]. Cells were purchased from the Amer-
ican Type Culture Collection and grown at 37°C in a
humidified 5% CO2 atmosphere in DMEM (Gibco/BRL,
Grand Island, NY, USA) supplemented with 10% fetal
bovine serum, 2 mM glutamine, 100 units/ml of penicil-
lin, and 100 μg/ml of streptomycin.
Structures of Andro, LA and AL-1Figure 1
Structures of Andro, LA and AL-1.Page 3 of 13
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RIN-m (5 × 104 cells/ml, 100 μl/well) were plated in 96-
well plates. After incubation for 24 h, cells were pretreated
with Andro, LA and AL-1 for 1 h. An equal volume of 1%
DMSO was added as a vehicle control (DMSO final con-
centration to 0.1%). Then, 500 μM H2O2 were added, and
the cells were incubated for another 24 h to induce cell
injury. Viability of cultured cells was determined by MTT
assay.
ROS inhibition assay
Luminol chemiluminescence (CL) was used to evaluate
intracellular oxidant production. RIN-m cells were
planted in 96-well plates and cultured in DMEM contain-
ing 10% fetal bovine serum and 450 mg/dl glucose. When
cells reached the loose confluent layer, medium was
replaced with DMEM containing 1% FBS and 100 mg/dl
glucose for 24 h. The cells were then exposed to 100, 275
and 450 mg/dl glucose or 0.1, 1 and 10 μM glibenclamide
under the presence of 100 mg/dl glucose for 2 h or pre-
treated with Andro, LA and AL-1 at a concentration of 1
μM for 1 h and exposed to 450 mg/dl glucose or 1 μM
glibenclamide for another 2 h. After treatment, 1 mM
luminol (in DMSO) was added to the cells (final concen-
tration of 50 μM). The time luminol was added was
recorded as time "0", and relative luminescence units
(RLU) were measured for 10 s every 2 min for a total of 30
min on a luminometer (TECAN, Männedorf, Switzer-
land). The areas under the chemiluminescence curves
(AUCCL) measured from time "0" to 30 min after adding
luminol were calculated using an Orange software
(OriginLab, Jersey, NJ, USA).
NF-κB assay by DLR system
RIN-m cells (1 × 105 cells/ml, 400 μl/well) in growth
medium (high glucose DMEM containing 10% FBS) were
plated in a 24-well plate, and were incubated for 24 h.
Plasmid pNF-κB-luc and PRL-TK (Promega) in a ratio of
50:1 were co-transfected into RIN-m cells as described by
the transfection guideline of lipofectamine 2000 (Invitro-
gen), and cultured in Opti-MEM medium (Invitrogen) for
4 h. Then medium was changed with the growth medium,
and the cells were cultured for another 12 h. Andro, LA,
AL-1 or vehicle control (DMSO final concentration to
0.1%) was added (final concentration: 1 μM) to pre-treat
cells for 1 h. IL-1β (5 ng/ml, PeproTech) and IFN-γ (50 ng/
ml, PeproTech) were then added, and the cells were incu-
bated for another 24 h. NF-κB expression was determined
by the dual luciferase reporter (DLR) assay kits
(Promega).
Statistics
Data were expressed as the mean ± S.D. for the number
(n) of animals in the group as indicated in table and fig-
ures. Repeated measures of analysis of variance were used
to analyze the changes in blood glucose and other param-
eters. Compare value less than 0.05 was considered signif-
icant.
Results
AL-1 attenuates alloxan-induced diabetes
Alloxan specifically targets pancreatic beta cells, where it
induces ROS, destroying the beta cells to cause diabetes.
Mice administered 60 mg/kg, i.v. of alloxan became
hyperglycemic after 3 days. The blood glucose reached
27.0 ± 1.2 mM (Table 1), a value within the acceptable
diabetic range. Drugs were administered, i.g. starting on
day 3 and continued daily for 6 days. On day 7, mice were
sacrificed, and various assays were performed.
AL-1 significantly lowers blood glucose
AL-1 markedly decreased blood glucose levels in diabetic
mice in a dose-dependent manner (Table 1). At 20, 40,
and 80 mg/kg, AL-1 decreased blood glucose by 32.5,
44.4, and 65.0%, respectively. This hypoglycemic effect
was equal to that of glibenclamide, a widely used anti-dia-
betic agent. AL-1 was 2-fold more potent than its parent
compound Andro. For example, at an equal molar dose,
AL-1 (80 mg/kg) lowered blood glucose by 65% while its
parent Andro (50 mg/kg) only lowered blood glucose by
32.3%.
AL-1 augments insulin levels
The diabetic animals had a significantly reduced level of
insulin (Fig. 2). Administration of AL-1 dose-dependently
increased insulin levels. Glibenclamide had a similar
activity in diabetic mice and normal ones. Andro had a
modest effect that did not reach statistical significance.
AL-1 preserves pancreatic beta cell morphology and function
The Islets of Langerhans of vehicle-treated normal mice
are large and oval-shaped (Fig. 3a). In sharp contrast, in
diabetic mice, the beta cell mass was obviously reduced
(Fig. 3b). At both the 20 and 80 mg/kg dose levels, AL-1
demonstrated significant protection of the beta cell mass
(Fig. 3c, d), and the effect was dose-dependent. The parent
compound Andro and the positive control glibenclamide
were also protective (Fig. 3e, f). These results suggest that
the hypoglycemic effects afforded by AL-1 is at least in part
due to its ability to protect the beta cell mass.
Immunohistochemical staining using an anti-insulin anti-
body demonstrates substantial staining in the healthy
islets of Langerhans in the pancreata of normal mice com-
pared to the much-reduced staining in the insulinopenic
diabetic animals (Fig. 3g–l). Experimental diabetic ani-
mals demonstrated insulin staining in the following
order: non-diabetic normals > diabetic + AL-1 80 mg/kg >
diabetic + Andro 50 mg/kg > diabetic + AL-1 20 mg/kg >
untreated diabetic. These results demonstrated beta cellPage 4 of 13
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with AL-1 and Andro. Surprisingly, although glibencla-
mide was shown to protect beta cell mass (Fig. 3f), only
low levels of insulin staining was found in the diabetic
animals receiving glibenclamide (Fig. 3l).
AL-1 stimulates GLUT4 translocation in the plasma 
membrane
Glucose transport, which depends on insulin-stimulated
translocation of glucose carriers within the cell mem-
brane, is the rate-limiting step in carbohydrate metabo-
lism of skeletal muscle [19]. Glucose transporters mediate
glucose transport across the cell membrane. GLUT4 is the
predominant form in skeletal muscle [20]. Diabetes is
characterized by reduced insulin-mediated glucose uptake
associated with reduced GLUT4 expression [21]. In dia-
betic models, Andro and LA are both known to reduce
blood glucose levels via upregulation of GLUT4 expres-
sion [11,22]. In the present study, the effect of AL-1 on
GLUT4 content in the plasma membrane of isolated
soleus muscles of diabetic mice was measured by western
blot analysis. The protein level of GLUT4 in the soleus
muscles of diabetic mice was only 49.5% that of the non-
diabetic mice (Fig. 4; p < 0.05 compared with normal con-
trols). Treatment of the diabetic mice with Andro (50 mg/
kg) or AL-1 (80 mg/kg) for 6 days elevated GLUT4 protein
levels to 94.6% and 84.7%, respectively, of that of the
non-diabetic mice (Fig. 4; p < 0.05 compared with diabetic
control). There was no significant difference between AL-
1 and Andro treated group.
AL-1 prevents H2O2-induced RIN-m cell death
Alloxan produces ROS which contribute to destruction of
pancreatic beta cells, leading to diabetes. The ability of AL-
1 to protect RIN-m pancreatic cells from H2O2-induced
oxidative damage was studied. The viability of RIN-m cells
cultured 24 h with 500 μM H2O2 was reduced to 42.7 ±
11.1% (Fig. 5). Pretreatment of the H2O2-treated RIN-m
cells with Andro, LA, AL-1 or a mixture of Andro and LA
at 0.01, 0.1 and 1 μM 30 min prior to H2O2 exposure for
60 min, provided significant protection. The viabilities of
cells at 24 h when incubated with 1 μM concentrations of
Andro, LA, AL-1 or a mixture of Andro and LA was 59.7 ±
5.9%, 59.7 ± 4.4%, 64.3 ± 11% and 62.2 ± 10.6% respec-
tively. AL-1 was more effective than either Andro or LA. At
0.1 μM, only LA and AL-1 provided a significant protective
effect. The protective effect of AL-1 was concentration-
dependent. The effect of the mixture of Andro and LA was
not better than AL-1, demonstrating that AL-1 was more
than a simple mixture of Andro and LA.
AL-1 quenches ROS production induced by high glucose 
and glibenclamide
High concentrations of glucose stimulate ROS production
both in vitro [23] and in vivo [24,25]. ROS subsequently
impair cellular function and activate apoptosis signaling,
leading to beta cell damage and death [26]. To investigate
the effect of AL-1 on glucose-induced ROS production in
vitro, RIN-m cells were incubated in the presence of high
concentrations of glucose, and the production of ROS was
measured. Exposure of RIN-m cells to increasing concen-
trations of glucose (100–450 mg/dl) for 2 h increased
ROS production in a concentration-dependent manner.
Pretreatment of the cells with 1 μM of Andro, LA or AL-1
effectively quenched the production of increased ROS. AL-
1 and LA were equally effective but more potent than
Andro (Fig. 6a).
Glibenclamide treatment decreases hyperglycemia in
alloxan-induced diabetic animals (Tab. 1) and protects
beta cell mass from significant loss (Fig. 3f). However, the
pancreatic beta cells of the glibenclamide-treated diabetic
have reduced immunoreactive insulin (Fig. 3l). To under-
stand these results, RIN-m cells were incubated with glib-
enclamide at increasing concentrations, and ROS
production was measured. Glibenclamide dose-depend-
ently increased ROS production (Fig. 6b), a finding previ-
ously reported [27]. Iwakura et al.[28] reported that
Table 1: Effect of AL-1 on blood glucose level in alloxan-induced diabetic mice.
Groups Blood glucose level (mM)
Day 0 Day 6 Changes (%)
Normal control 5.8 ± 1.5 5.9 ± 1.7 +1.7
Diabetic control 27.0 ± 1.2 a 25.4 ± 7.8 -5.9
Diabetic + AL-1 (20 mg/kg) 24.9 ± 3.1a 16.8 ± 2.4 b -32.5
Diabetic +AL-1 (40 mg/kg) 25.0 ± 2.7 a 13.9 ± 3.4 c -44.4
Diabetic + AL-1 (80 mg/kg) 24.6 ± 3.2 a 8.6 ± 3.1 c, d -65.0
Diabetic + Andro (50 mg/kg) 24.8 ± 3.0 a 16.8 ± 2.1 b -32.3
Diabetic + Gli (1.2 mg/kg) 24.7 ± 5.1 a 10.1 ± 3.0 c, d -59.1
72 h after alloxan administration (Day 0), drugs were given by intragastric administration once daily for 6 days. On day 0 and day 6, fasting blood 
glucose levels were determined. Values are means ± S.D. of 6 mice. aP < 0.01 vs. normal mice; bP < 0.05 vs. value on day 0; cP < 0.01 vs. value on day 
0; dP < 0.05 vs. Andro treatment on day 6. Gli: glibenclamide.Page 5 of 13
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ent manner by continuous exposure to glibenclamide at
concentrations of 0.1 to 100 μM. When the cells were
incubated in the presence of both 1 μM glibenclamide
and 1 μM of Andro, LA or AL-1, the ROS induced by glib-
enclamide were almost completely eliminated (Fig. 6b).
AL-1 inhibits NF-κB activation induced by IL-1β and IFN-γ 
inRIN-m cells
Activation of NF-κB impairs the function of beta cells and
contributes to cellular death [29,30]. A NF-κB reporter
assay was used to investigate the effect of AL-1 on NF-κB
activation. Cells were co-transfected with pNF-κB-luc and
PRL-TK plasmids, pre-incubated with Andro, LA, AL-1 or
vehicle followed by addition of IL-1β and IFN-γ. AL-1 at
0.1 and 1 μM significantly inhibited luciferase activity of
the NF-κB reporter construct (Fig. 7; p < 0.01 compared
with vehicle control). In fact, at 1 μM, AL-1 completely
blocked IL-1β and IFN-γ-induced NF-κB activation. By
contrast, Andro showed substantial NF-κB inhibition only
at the highest concentration of 1 μM. AL-1 was at least 10-
fold more potent than the parent compound Andro in this
experiment.
Hidalgo et al. [31] reported that Andro at 5 and 50 μM sig-
nificantly inhibited PAF-induced luciferase activity in a
NF-κB reporter construct. Zhang and Frei [32] found that
preincubation of human aortic endothelial cells for 48 h
with LA (0.05–1 mM) inhibited TNF-α (10 U/ml)-
induced NF-κB binding activity in a dose-dependent man-
ner. In the presence of 0.5 mM LA, the TNF-α-induced NF-
κB activation was inhibited by 81%. Thus, in the present
experiment, a 1 μM concentration of LA may be too low
to suppress NF-κB activation.
Discussion
AL-1 is a new chemical entity derived by covalently link-
ing andrographolide and lipoic acid, two molecules previ-
ously shown to have anti-diabetic properties [7,11,13-15].
In the present study, we demonstrate that alloxan-induced
diabetic mice treated with AL-1 have 1) normalized blood
glucose levels; 2) augmented blood insulin levels; 3) pro-
tected beta cell mass and function. These data suggest that
AL-1 is a potential new anti-diabetic agent.
Types 1 diabetes is characterized by the loss of pancreatic
beta cells. A novel anti-diabetic agent must have a strong
Effect of AL-1 on serum insulin level in diabetic miceFigure 2
Effect of AL-1 on serum insulin level in diabetic mice. Alloxan-induced diabetic mice were treated with AL-1, Andro or 
glibenclamide by intragastric administration once daily for 6 days. On day 6, serum insulin levels were detected. Each column 
represents the mean ± S.D. of 6 mice. *P < 0.05 vs. normal group, **P < 0.01 vs. diabetic group. Gli: glibenclamide.Page 6 of 13
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Pathologic and immunohistochemical analysis of mouse pancreasFigure 3
Pathologic and immunohistochemical analysis of mouse pancreas. Alloxan-induced diabetic mice were treated with 
Andro, AL-1 or glibenclamide for 6 days, the the pancreas were isolated for hematoxylin and eosin staining or anti-insulin 
immuohistaining. A, Representative morphology of pancreatic islets. a-f: hematoxylin and eosin staining. Arrow showed the 
islets' position, scale bar: 50 μm; g-l: immunostaining against insulin as visualized by the HRP-DAB method, scale bar: 50 μm. a, 
g, no-diabetic control; b, h, diabetic + vehicle control; c, i, diabetic + AL-1 20 mg treatment; d, j, diabetic +AL-1 80 mg treat-
ment; e, k, diabetic + Andro 50 mg treatment; f, l, diabetic + glibenclamide 1.2 mg treatemnt. B, Statistic analysis of average area 
of per islets among different groups (n = 6). *P < 0.01 vs. normal group, **P < 0.01 vs. diabetic group.
Journal of Translational Medicine 2009, 7:62 http://www.translational-medicine.com/content/7/1/62hypoglycemic effect; however, the optimal agent must
also be able to protect and preserve pancreatic beta cell
mass and function. In our experiments, alloxan was used
to induce diabetes. Alloxan produces oxygen free radicals
to induce dysfunction and death of pancreatic beta cells
[33]. It is known that alloxan-induced hyperglycemia can
be reversible due to regeneration of beta cells, and the
regeneration is early, i.e., in days [34,35]. Based on these
findings, we thought that when the animals were admin-
istered alloxan, their pancreatic beta cells were damaged
but the limiting threshold for reversibility of decreased
beta cell mass had not been passed. AL-1, given 3 days
after alloxan administration, quickly lowered blood glu-
cose, leading to a reduction of the damaging ROS and
thereby protecting beta cells from further damage and
facilitated their regeneration. For the same reasons,Andro
and glibenclamide also stimulated beta cell regeneration.
When an anti-insulin antibody was applied to the beta
cells, we found that the beta cells of the AL-1 treated ani-
mals have significant amounts of insulin, suggesting that
these cells can secrete insulin. In a sharp contrast to the
AL-1-treated animals, we found little insulin in the pan-
creata of the glibenclamide-treated animals despite the
fact that these animals had fairly large beta cell mass (Fig.
3), suggesting that the ability of these beta cells to secrete
insulin has been impaired. However, results as depicted in
Fig. 2 showed that the glibenclamide-treated animals had
AL-1 elevated GLUT4 translocation to the plasma membrane of soleus musclesFigure 4
AL-1 elevated GLUT4 translocation to the plasma membrane of soleus muscles. Alloxan-induced diabetic mice 
were treated with AL-1 at 80 mg/kg, Andro at 50 mg/kg or vehicle control by intragastric administration once daily for 6 days. 
The soleus muscles were isolated and GLUT4 contents in plasma membrane were analyzed by western blot. (A) shows repre-
sentative GLUT4 protein bands at 54 kDa; (B) shows the relative GLUT4 content normalized by internal standard, β-actin. *P 
< 0.05 vs. normal group, **P < 0.05 vs. diabetic group, n = 6.Page 8 of 13
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mals. The reason behind the discrepancy between these
results is not known at the present time, and needs to be
further investigated.
Antioxidants such as N-acetyl-L-cysteine, vitamin C, vita-
min E, and various combinations of these agents have
been known to protect islet beta cells in diabetic animal
models [36]. Previous studies have shown that Andro and
LA are both potent antioxidants [37,38]. Results in Fig. 5
show that AL-1 had protective effects toward H2O2-
induced oxidative damage in RIN-m cells at concentra-
tions from 0.01–1 μM, which are achievable in animals.
Thus, it is likely that, in diabetic animals, AL-1 functions
as an antioxidant to quench ROS and protect beta cells.
This point is further supported by data in Fig. 6a, where
AL-1 markedly suppressed glucose-induced ROS produc-
tion in RIN-m cells at 1 μM. In contrast to what is found
with AL-1, glibenclamide stimulated ROS production at a
low concentration of 0.1 μM (Fig. 6b). AL-1, Andro or LA
at 1 μM completely quenched the ROS induced by 1 μM
of glibenclamide. These data and those reported by others
[27,28] provide a likely explanation to the notion that
there were a significant amount of insulin in the AL-1
treated mice but not in those treated with glibenclamide.
Previous investigations suggest that increased oxidative
stress and NF-κB activation are potential mechanisms of
action for hyperglycemic toxicity on pancreatic beta cells
(([39,40]. In vitro evidence suggests that activation of NF-
κB contributes to triggering of beta cell apoptosis [29].
The fact that AL-1 completely suppressed IL-1β and IFN-γ
stimulated NF-κB expression at concentrations ranging
from 0.1 to 1 μM (Fig. 7) and that overexpression of NF-
κB leads to overproduction of ROS [41,42] suggest that
AL-1 reduces ROS production by inhibiting NF-κB activa-
tion in addition to directly scavenging ROS through its
anti-oxidative properties.
Andro is reported to react with the SH group of cysteine 62
on the p50 subunit of the NF-κB, which blocks the bind-
ing of NF-κB to the promoters of their target genes, pre-
venting NF-κB activation [43]. LA was reported to inhibit
NF-κB activation via modulation of the cellular thiore-
doxin system [44] or by direct interaction with the target
DNA [45]. Further studies are needed to uncover how the
combination drug AL-1 inhibits NF-κB.
Both Andro [11,46] and LA [22] are reported to lower
blood glucose levels of diabetic animals by increasing
GLUT4 expression. Western blot analysis of soleus muscle
Effect of AL-1 on H2O2-induce RIN-m cell viabilityFigure 5
Effect of AL-1 on H2O2-induce RIN-m cell viability. RIN-m cells were pretreated with Andro, LA, AL-1 or Andro + LA 
(0.01–1 μM) following stimulation with 500 μM H2O2for 24 h. Then cell viability was determined by MTT assay. Results were 
expressed as the % of optical density of normal group (non-H2O2 + vehicle treated), n = 8 replicates per group. *P < 0.01 vs. 
non-H2O2 treated group, **P < 0.05 and † P < 0.01 vs. H2O2 treated group.Page 9 of 13
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AL-1 effectively quenched ROS production induced by high glucose and glibenclamideFigure 6
AL-1 effectively quenched ROS production induced by high glucose and glibenclamide. RIN-m cells were pre-
treated with Andro, LA or AL-1 (1 μM) following stimulation with high glucose (275 and 450 mg/dl) or glibenclamide (0.1 and 
1 μM) for 2 h. Then the ROS production was measured. Results were calculated by % of AUCCL at 100 mg/ml glucose and 0 μM glibenclamide. (A) ROS production induced by high glucose. *P < 0.05 vs. 450 mg/dl glucose treatment alone; (B) ROS pro-
duction induced by glibenclamide (Gli). **P < 0.05 vs. 1 μM glibenclamide treatment alone, n = 8 replicates per group.
Journal of Translational Medicine 2009, 7:62 http://www.translational-medicine.com/content/7/1/62confirmed that both Andro and AL-1 treatment resulted in
significantly elevated levels of GLUT4 protein. These data
suggest that AL-1 stimulated GLUT4 translocation in the
plasma membrane of soleus muscles, leading to increased
glucose utilization. Andro has been reported to lower
blood glucose via the alpha-adrenoceptor [46] or by inhi-
bition of alpha-glycosidase [47]. In present studies, Andro
at 50 mg/kg lowered blood glucose and stimulated
GLUT4 translocation. Because the reported IC50 for
Andro-inhibition of alpha-glycosidase is above 100 μM,
this is unlikely to be the mechanism; however, further
mechanistic studies are indicated.
Conclusion
The actions of AL-1 can be summarized as follows: to
lower blood glucose, AL-1 protects beta cell mass and pre-
serves their insulin-secreting function, and stimulates
GLUT4 translocation to increase glucose utilization. For
beta cell protection, AL-1 directly scavenges ROS through
its antioxidant properties and reduces ROS production by
inhibiting activation of NF-κB. Although most clinically
useful anti-diabetic agents reduce blood glucose levels
directly or indirectly, few are reported to also protect and
preserve beta cell mass and insulin-secreting functions.
AL-1 possesses both of these capabilities via multiple
mechanisms. Further studies to explore the mechanisms
of action of this promising new anti-diabetic agent are
warranted.
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AL-1 inhibited NF-κB activation stimulated by IL-1β and IFN-γ in RIN-m cellsFigure 7
AL-1 inhibited NF-κB activation stimulated by IL-1β and IFN-γ in RIN-m cells. RIN-m cells were co-transfected by 
pNF-κB-luc and PRL-TK plasmids. After pretreament with 0.01–1 μM Andro, LA or AL-1, cells then were stimulated by IL-1β 
(5 ng/ml) and IFN-γ (50 ng/ml) for 24 h. NF-κB activity was detected by DLR kit. *P < 0.01 vs. normal control, **P < 0.05 and † 
P < 0.01 vs. vehicle control, n = 8 replicates per group.Page 11 of 13
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